Key clinical point: There is a lack of evidence about bleeding rates, joint damage, quality of life, and costs of care for patients with mild hemophilia A.
Major finding: Among six studies that reported the percentage of patients with bleeding events, those numbers ranged from 5.5% (1/18) to 90.7% (68/75).
Study details: A literature review of 17 studies with data on 3,213 patients with mild hemophilia A aged 13 years or older.
Disclosures: Seven of the eight researchers reported relationships, including employment, with BioMarin. Dr. Peyvandi reported relationships with Sanofi, Grifols, Novo Nordisk, Roche, Takeda, Sobi, Bioverativ, Spark Therapeutics, Sysmex, and CSL Behring.
Peyvandi F et al. Haemophilia. 2019 Jul 11. doi: 10.1111/hae.13777.